| Date | Title | Description |
| 02.08.2022 | Red Meat Raises Your Heart Risk, and Scientists May Know Why | TUESDAY, Aug. 2, 2022 (HealthDay News) -- A daily hamburger might raise the risk of developing heart disease, but not necessarily for the reasons people often think, new research suggests.
The study of nearly 4,000 older Americans found wha... |
| 20.10.2017 | Term Sheet — Friday, October 20 | TRENDY IPO
Happy Friday, Term Sheet readers.
Paid Content Securing the enterprise without boundaries From ExtraHop
Stitch Fix has been hyper-focused on profitability in fiscal year 2017. The company increased its revenue 13-fold since 2014 ... |
| 18.10.2017 | Quest Diagnostics’ Cleveland HeartLab acquisition reflects personalized medicine trend | Quest Diagnostics has snapped up Cleveland Clinic spinoff Cleveland HeartLab in an equity deal and formed a strategic collaboration with the health system. The acquisition gives the national clinical lab testing business access to the Heart... |
| 18.03.2015 | Biomeme wants you to take its latest DIY genomic test | It’s right before the test when I start to get nervous.
Like, my heart starts pounding, which is strange because we’ve been talking about this test for the last 30 minutes and I felt just fine.
We’re in the N3rd Street offices of Biomeme, a... |
| 25.04.2013 | Startup that assesses heart disease risk and uses virtual coaches to improve outcomes raises $5.85 million | Last year when Richter presented before the Villanova Entrepreneurs Network he said a near term goal would be to expand the Houston, Texas business to the Philadelphia region.
CardioVIP has been working with Cleveland HeartLab to analyze da... |
| 13.09.2012 | Heart disease startup using “iCoaches” and biosensors to improve patient outcomes | Richter, who is also a co-founder and principal with Jericho Equity Partners, said a near-term goal is to expand the Houston, Texas-based business to the Philadelphia region. Richter has worked for companies like CorSolutions Medical, which... |
| 23.08.2011 | Cleveland Heartlab Pumps $18.4M Series B |
Excel Venture Management and HealthCare Ventures, both of Boston, led the round. The company’s existing investors also participated.
>> Click here for more funding data on Cleveland Heartlab Pumps
>> To export Cleveland He... |
| 22.08.2011 | Cleveland HeartLab Completes $18.4M Series B Financing Round | Cleveland HeartLab Inc. (CHL), a specialty clinical laboratory and disease management company, completed an $18.4m Series B financing round.
The investment was led by Excel Venture Management and HealthCare Ventures, with participation from... |
| 22.08.2011 | Biomarker test firm Cleveland HeartLab closes $18.4M investment | The round was led by Excel Venture Management of Boston and HealthCare Ventures of Cambridge, Massachusetts, with participation from existing investors.
Cleveland HeartLab is a clinical reference laboratory that does an array of lipid and i... |
| 26.07.2011 | Biomarker test firm Cleveland HeartLab rejects buyer, picks ‘home’ | Cleveland HeartLab, which makes a biomarker-based heart test, has rebuffed an acquisition offer and instead taken an Ohio tax credit to keep growing the company, according to Ohio government officials.
The company received a six-year tax cr... |
| 30.03.2011 | Cleveland Clinic: Both hospital and startup incubator | $28 million may be just the beginning.
That’s the return Cleveland Clinic received after the $78 million sale of Clinic spinoff Intelect Medical to Boston Scientific Corp. (NYSE:BSX).
It was the largest of three exits so far for companies a... |
| 29.03.2011 | Cleveland Clinic’s most promising startups | Promoted
Clinical Care Capacity Planning
Learn how to manage clinical care capacity more efficiently during uncertain times.
SAP
Promoted
This Patient Experience Checklist Is Your Key To Success in 2021
As healthcare systems strive to recov... |
| 13.08.2010 | Cleveland HeartLab business has ‘exploded’ (in a good way) | Clients have adopted Cleveland HeartLab’s services at a rate “beyond what we had hoped for,” Orville said. He and his colleagues started the year doing hundreds of tests per month. Now, they are doing thousands of tests per month.
To accomm... |
| 14.06.2010 | Cleveland Clinic strikes research deal for ‘good cholesterol’ drug | Another sidebar: Cleveland Clinic star cardiologist and drug industry watchdog Dr. Steven Nissen studied Lipitor in the early 2000s when it was owned by Esperion, hailing the drug for slowing the buildup of “bad cholesterol,” also known as ... |
| 18.03.2010 | Cardiac biomarker gets second life | By Mary Vanac
Jake Orville always thought the cardiac inflammation biomarker developed by Dr. Stanley Hazen and his colleagues at the Cleveland Clinic was a valuable and proven technology. But his efforts to make it a commercial success for... |
| 17.03.2010 | Cleveland HeartLab: How to go to market with diagnostic test? | Based on Hazen’s research, Cleveland Clinic spin-off company PrognostiX had commercialized a test for myeloperoxidase–an enzyme that indicates inflammation in the artery walls of the heart, which can predict fatal heart attacks or strokes. ... |
| 06.03.2010 | Weekend Rounds: Cleveland HeartLab raises $3M to expand outside Ohio | • Despite its name, Pedal Brain LLC’s ambitions far exceed bicycles. Replacing “Pedal” with “Health” starts to describe what this angel-backed start-up wants to do. Pedal Brain recently struck a deal with HED Cycling Products USA to sell a ... |
| 02.03.2010 | Cleveland HeartLab completes $3M funding to expand, develop more inflammation tests | Cleveland HeartLab is a clinical reference laboratory specializing in next-generation cardiovascular disease prevention, diagnosis and management. The company operates a CLIA-certified and CAP-accredited lab where it analyzes samples for ma... |
| 02.03.2010 | Cleveland HeartLab Raises $3M | Cleveland HeartLab LLC (CHL), a Cleveland, Ohio-based clinical laboratory and disease management company focused on offering propriety diagnostic tests based on molecular biomarkers, has completed a $3.0m financing round.
CHL’s new sharehol... |
| 18.12.2009 | Clinic spin-off Cleveland Heartlab raises $2.5M for cardiac-risk test | The Web site of another Cleveland Clinic spin-off, PrognostiX, says that company is marketing the CardioMPO product. It’s unclear what relationship, if any, exists between the two companies.
A Cleveland Clinic spokesman wasn’t available for... |
| - | Cleveland HeartLab completes $3M funding to expand, develop more inflammation tests | Updated 4:24 p.m.
Cleveland Clinic spinoff Cleveland HeartLab has completed a $3 million fundraising round, and named its executives and advisers.
Investors in the round included Glengary LLC, Second Generation Ltd. and Zapis Capital Group ... |
| - | Heart disease startup using “iCoaches” and biosensors to improve patient outcomes | Cardiovascular disease treatment startup CardioVIP has raised two-thirds of a $3 million series B financing round to create better outcomes for cardiovascular disease.
The company presented as part of an angel investor pitching event held b... |
| - | I’m a nutritionist from Japan, home to the world’s longest-living people—here are 5 longevity foods we eat every day | I grew up in Japan, where I was taught from a young age to think of food as medicine. My grandmother is 92, and she also credits her longevity to eating the right foods.
Japan is home to some of the world’s longest-living people: There are ... |
| - | Cleveland Clinic strikes research deal for ‘good cholesterol’ drug | The Cleveland Clinic will work with Esperion Therapeutics Inc. to develop “good cholesterol” therapies to fight cardiovascular disease.
Privately held biopharmaceutical company Esperion in Plymouth, Mich. — which discovers, develops and com... |
| - | Biomarker test firm Cleveland HeartLab rejects buyer, picks ‘home’ | Cleveland HeartLab, which makes a biomarker-based heart test, has rebuffed an acquisition offer and instead taken an Ohio tax credit to keep growing the company, according to Ohio government officials.
The company received a six-year tax cr... |
| - | Clinic spin-off Cleveland Heartlab raises $2.5M for cardiac-risk test | CLEVELAND, Ohio — A new Cleveland Clinic spin-off company that’s developing a test to predict cardiac risk has received a $2.5 million investment.
The source of the investment in newly created Cleveland Heartlab LLC was not disclosed in a s... |
| - | Cleveland HeartLab business has ‘exploded’ (in a good way) | In the words of Cleveland HeartLab CEO Jake Orville, business has “exploded” since the beginning of the year, just months after his company launched a proprietary test for cardiac inflammation under a fee-for-service model.
Cleveland HeartL... |
| - | Biomarker test firm Cleveland HeartLab closes $18.4M investment | Biomarker test-maker Cleveland HeartLab has closed an $18.4 million series B round of funding, which was led by two Boston-area investors.
The size of the round is a testament to the explosive growth that the young company has achieved in l... |
| - | Quest Diagnostics’ Cleveland HeartLab acquisition reflects personalized medicine trend | Quest Diagnostics has snapped up Cleveland Clinic spinoff Cleveland HeartLab in an equity deal and formed a strategic collaboration with the health system. The acquisition gives the national clinical lab testing business access to the Heart... |
| - | Weekend Rounds: Cleveland HeartLab raises $3M to expand outside Ohio | Here are some of the top stories at MedCity News this week:
• Cleveland Clinic spinoff Cleveland HeartLab completed a $3 million fundraising round, and named its executives and advisers. The clinical reference laboratory specializing in nex... |
| - | Cleveland Clinic’s most promising startups | $28 million may be just the beginning.
That’s the return Cleveland Clinic received after the $78 million sale of Clinic spinoff Intelect Medical to Boston Scientific (NYSE:BSX). It was the largest of three exits so far for companies affilia... |
| - | Cleveland HeartLab: How to go to market with diagnostic test? | Updated 4:29 p.m., March 18, 2010
The cardiac inflammation biomarker developed by Dr. Stanley Hazen and his colleagues at the Cleveland Clinic was a valuable and proven technology, thought Jake Orville, president and chief executive of Clev... |
| - | Startup that assesses heart disease risk and uses virtual coaches to improve outcomes raises $5.85 million | Update A healthcare startup that wants to improve outcomes for people at risk for developing heart disease has raised $5.8 million. The company’s solution involves calculating each individual’s risk of heart disease using a series of algori... |
